La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bank of Marin a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bank of Marin..

Bank of Marin (NASDAQ:BMRC) Azioni, Catena delle Opzioni

Bank of Marin

Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.

Bank of Marin Bancorp

WIIM

ABCB

ACNB

AMAL

AMTB

AROW

BANF

BANR

BCAL

BFST

BHLB

BHRB

BMRC

BOKF

BPOP

BRKL

BSRR

BSVN

BUSE

CARE

CASH

CATY

CBAN

CBNK

CBSH

CCBG

CCNE

CFFN

CHCO

CLBK

CNOB

COFS

CTBI

CUBI

CVBF

CZFS

DCOM

EBTC

EFSC

EGBN

EQBK

EWBC

FBIZ

FBMS

FBNC

FCBC

FCNCA

FFBC

FFIC

FFIN

FFWM

FIBK

FISI

FLIC

FMAO

FMBH

FMNB

FNLC

FRBA

FRME

FRST

FSBC

GABC

GBCI

GCBC

GNTY

GSBC

HAFC

HBCP

HBNC

HFBL

HFWA

HIFS

HMST

HOMB

HONE

HOPE

HTBI

HTBK

HTLF

Shares of banking-related companies are trading higher after Donald Trump won the US presidential election.

Earnings

News

Bank of Marin Q3 2024 Adj. EPS $0.28 Beats $0.27 Estimate, Sales $24.269M Miss $24.919M Estimate

Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) will release its quarterly earnings report on Monday, 2024-10-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Bank of Marin to report an earnings per share (EPS) of $0.26.
The announcement from Bank of Marin is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.11 in the last quarter, leading to a 8.72% increase in the share price on the following day.
Here's a look at Bank of Marin's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.17</td>
<td>0.26</td>
<td>0.32</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.06</td>
<td>0.18</td>
<td>0.30</td>
<td>0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729875700_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank of Marin were trading at $21.94 as of October 24. Over the last 52-week period, shares are up 30.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BMRC/earnings">To track all earnings releases for Bank of Marin visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Bank of Marin

DA Davidson analyst upgraded Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) to Buy from Neutral and <a target="_blank" href="https://www.benzinga.com/quote/bmrc/analyst-ratings" rel="noreferrer noopener">raised the price target to $24 from $21</a>.
The analyst writes that the Fed&#8217;s potential shift to lower rates has enhanced their earnings outlook for BMRC and led to the belief that the bank&#8217;s credit risks have somewhat diminished.
Consequently, the analyst increased the 2025 EPS estimate by 10%, primarily due to a more optimistic forecast for NIM/NII.
Furthermore, the anticipated relief from interest rates is expected to alleviate some pressure on office CRE and lessen overall investor concerns regarding the broader credit quality landscape, adds the analyst.
The analyst says that the bank sold low-yielding securities to reduce borrowings and invest in higher-yielding assets in the second quarter, expected to raise annualized NIM by about 30 basis points starting in 3Q24 and generate $0.46 in EPS accretion over the next four quarters, representing a three-year payback.
Additionally, a 200 basis point rate reduction could boost NII by 1.8% in the first year, leading the analyst to project NIM will surpass 3.00% by the end of 2025.
The analyst says that while BMRC&#8217;s credit issues aren&#8217;t fully resolved, the recent 50 basis point Fed rate cut offers relief for maturing loans and increases the chances of a soft landing, easing investor concerns over credit quality.
The analyst estimates EPS of $(0.70) in 2024 and $1.35 (up from $1.23) in 2025.
Price Action: BMRC shares are up 4.53% at $21.02 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41277228" target="_blank" rel="noreferrer noopener">PlayStation Plus October 2024: Dead Island 2 Leads Spooky Lineup Of 14 Games</a></li>
</ul>

Analyst Color

Equities

Large Cap

Upgrades

Price Target

Analyst Ratings

Trading Ideas

Bank Of Marin Set For Earnings Surge, Analyst Raises 2025 Forecast Amid Interest Rate Cuts

DA Davidson analyst Jeff Rulis upgrades Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) from Neutral to Buy and announces $24 price target.

DA Davidson Upgrades Bank of Marin to Buy, Announces $24 Price Target

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Outperform and raises the price target from $21 to $23.

Keefe, Bruyette & Woods Maintains Outperform on Bank of Marin, Raises Price Target to $23

Bank of Marin (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrc#NASDAQ">BMRC</a>) reported $25.25 million in revenue for the quarter ended June 2024, representing a year-over-year decline of 6%. EPS of $0.06 for the same period compares to $0.28 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $25.85 million, representing a surprise of -2.31%. The company delivered an EPS surprise of -68.42%, with the consensus EPS estimate being $0.19.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company&#39;s financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock&#39;s price performance.
Here is how Bank of Marin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
<ul>
<li>Net interest margin: 2.5% versus 2.6% estimated by three analysts on average.</li>
<li>Efficiency Ratio: -300.4% compared to the 80.8% average estimate based on three analysts.</li>
<li>Average Balance - Total interest earning assets: $3.56 billion versus $3.60 billion estimated by two analysts on average.</li>
<li>Total non-accrual loans: $33.68 million compared to the $6.67 million average estimate based on two analysts.</li>
<li>Net interest income: $22.47 million versus the three-analyst average estimate of $22.88 million.</li>
<li>Total non-interest income: $2.79 million versus $2.77 million estimated by three analysts on average.</li>
<li>Net Interest Income: $22.64 million compared to the $23.06 million average estimate based on two analysts.</li>
</ul>
Shares of Bank of Marin have returned +38.1% over the past month versus the Zacks S&amp;P 500 composite&#39;s -0.2% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
<a href="https://www.zacks.com/stock/news/2311047/compared-to-estimates-bank-of-marin-bmrc-q2-earnings-a-look-at-key-metrics?cid=CS-BENZ-FT-fundamental_analysis|nfm-2311047">To read this article on Zacks.com click here.</a>

Small Cap

Markets

Compared to Estimates, Bank of Marin Q2 Earnings: A Look at Key Metrics

Shares of Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) fell sharply during Monday's session after the company reported <a href="https://www.benzinga.com/quote/BMRC/earnings">worse-than-expected quarterly earnings.</a>
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares climbed 128% to $2.8535.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) gained 61.6% to $4.75 after jumping around 56% on Friday.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 37.8% to $0.6232 after gaining 11% on Friday.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) gained 34.4% to $12.25.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 26.8% to $14.76.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) jumped 24.2% to $0.4366.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) rose 23.5% to $2.9860.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) rose 18.4% to $4.19.</li>
<li>Cepton, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 16.1% to $15.35.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) gained 9.5% to $5.09.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 28.6% to $0.1830 after gaining 6% on Friday.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) fell 26.4% to $14.90 following downbeat quarterly results.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) declined 18.5% to $8.84.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 17.5% to $0.2544.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 17% to $1.5243.</li>
<li>Integra Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#NYSE">ITRG</a>) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 12.8% to $14.01.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) fell 10.5% to $9.60.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) fell 6.3% to $37.53.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40011559/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Intraday Update

Movers

AVXL

CERO

CGTX

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LIPO

LUXH

MESO

NIPG

NISN

NLSP

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

VERO

VTVT

VTYX

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

Bank of Marin shares are trading lower after the company reported worse-than-expected Q2 earnings.

Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.18 by 66.67 percent. This is a 78.57 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million by 3.95 percent. This is a 16.38 percent decrease over sales of $26.87 million the same period last year.

Bank of Marin Q2 Adj $0.06 Misses $0.18 Estimate, Sales $22.47M Miss $23.39M Estimate

As of July 29, 2024, five stocks in the financials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Columbia Banking System Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>On July 25, Columbia Banking System reported better-than-expected second-quarter earnings results. &#8220;Our second quarter results reflect continued progress on our targeted actions to improve our financial performance and drive shareholder value,&#8221; said Clint Stein, President and CEO. The company's stock gained around 36% over the past month and has a <a href="https://www.benzinga.com/quote/COLB">52-week high of $27.94</a>.</li>
<li>RSI Value: 86.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>COLB Price Action: Shares of Columbia Banking System gained 11.6% to close at $26.99 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Hartford Financial Services Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>)</h3>
<ul>
<li>On July 25, Hartford Financial reported better-than-expected second-quarter earnings results. &#8220;The Hartford&#8217;s second quarter 2024 financial results were outstanding with a trailing 12-month core earnings ROE of 17.4 percent,&#8221; said The Hartford&#8217;s Chairman and CEO Christopher Swift. The company's stock gained around 8% over the past five days and <a href="https://www.benzinga.com/quote/HIG">has a 52-week high</a> of $109.68.</li>
<li>RSI Value: 79.84</li>
<li>HIG Price Action: Shares of Hartford Financial gained 7.1% to close at $109.63 on Friday.</li>
</ul>
<h3 class="wp-block-heading">KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>)</h3>
<ul>
<li>On July 18, KeyCorp posted better-than-expected quarterly sales. Chairman and CEO, Chris Gorman said, &#8220;This was a solid quarter for Key as we continued to execute on our clearly defined path to enhanced profitability. Sequentially, net interest income grew as we benefited from fixed asset repricing and continued to grow client deposits while the pace of deposit repricing slowed.&#8221; The company's stock gained around 16% over the past month and has a <a href="https://www.benzinga.com/quote/KEY">52-week high</a> of $16.47.</li>
<li>RSI Value: 70.06</li>
<li>KEY Price Action: Shares of KeyCorp gained 2.1% to close at $16.46 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>)</h3>
<ul>
<li>On July 22, Zions Bancorporation reported better-than-expected quarterly financial results. Harris H. Simmons, Chairman and CEO of Zions Bancorporation, commented, &#8220;Second quarter results demonstrated continued improvement in our net interest margin, effective expense management, strong credit quality as reflected in continued low loan losses, and strengthened capital.&#8221; The company's stock jumped around 21% over the past month and has a 52-week high of $53.32.</li>
<li>RSI Value: 71.11</li>
<li>ZION Price Action: Shares of Zions Bancorporation gained 1% to close at $52.29 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>)</h3>
<ul>
<li>On June 28, Keefe, Bruyette &amp; Woods analyst Wood Lay maintained Bank of Marin with an Outperform and maintained a $21 price target. The company's stock jumped around 36% over the past month and <a href="https://www.benzinga.com/quote/BMRC">has a 52-week high</a> of $22.79.</li>
<li>RSI Value: 72.99</li>
<li>BMRC Price Action: Shares of Bank of Marin Bancorp gained 1.5% to close at $22.35 on Friday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">&#8216;</a></li>
</ul>

Short Ideas

Pre-Market Outlook

COLB

ZION

Top 5 Financials Stocks That May Fall Off A Cliff This Month

Avidbank Holdings Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/avbh#OTC">AVBH</a>) came out with quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -32.35%. A quarter ago, it was expected that this company would post earnings of $0.69 per share when it actually produced earnings of $0.69, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Avidbank Holdings, which belongs to the Zacks Banks - West industry, posted revenues of $19.62 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 4.53%. This compares to year-ago revenues of $18.58 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Avidbank Holdings shares have lost about 9.1% since the beginning of the year versus the S&amp;P 500&#39;s gain of 15.4%.
What&#39;s Next for Avidbank Holdings?
While Avidbank Holdings has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Avidbank Holdings: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.69 on $21.05 million in revenues for the coming quarter and $2.73 on $83.31 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - West is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Bank of Marin (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrc#NASDAQ">BMRC</a>), has yet to report results for the quarter ended June 2024. The results are expected to be released on July 29.
This bank holding company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -32.1%. The consensus EPS estimate for the quarter has been revised 31.9% higher over the last 30 days to the current level.
Bank of Marin&#39;s revenues are expected to be $25.85 million, down 3.8% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2305811/avidbank-holdings-inc-avbh-misses-q2-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2305811">To read this article on Zacks.com click here.</a>

Earnings Misses

AVBH

Avidbank Holdings Inc. Misses Q2 Earnings and Revenue Estimates

JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) remains well-positioned for growth on the back of higher rates, strategic acquisitions and restructuring initiatives, and a resurgence in global deal-making activities. However, challenges in improving fee income because of high mortgage rates and volatile capital market revenues are woes.
JPMorgan&#39;s net interest income (NII) and net yield on interest-earning assets are likely to experience decent growth as the Federal Reserve is expected to keep interest rates high in the near term. However, rising funding and deposit costs will continue to exert pressure on both to some degree. Though NII dipped in 2020 and 2021 amid the low interest rate environment, the metric reflected a five-year (2018-2023) compound annual growth rate (CAGR) of 10.1%. This rise was partially driven by the First Republic Bank&#39;s acquisition in 2023. Similarly, net yield on interest-earning assets expanded to 2.70% in 2023 from 2% in 2022. The uptrend for both metrics continued during the first quarter of 2024 on a year-over-year basis. The company projects NII in 2024 to rise roughly 2.5% to approximately $92 billion.
Despite the rapid growth of mobile and online banking options, JPM remains focused on its footprint expansion in new regions. In February 2024, the company announced plans to open more than 500 new branches by 2027 to strengthen its position as the bank with the largest branch network and a presence in all 48 states of the United States. The company commenced its digital retail bank Chase in the U.K. in 2021 and intends to expand the accessibility of its digital bank across the European Union. JPMorgan is also focused on strengthening the Commercial &amp; Investment Bank&nbsp;and Asset &amp; Wealth Management businesses in China.
While global deal-making activities nearly came to a grinding halt at the start of 2022, JPMorgan remained a top-ranked entity in terms of global investment banking (IB) fees. While the company&#39;s total IB fees (in the CIB segment) slumped 59% in 2022 and 5% in 2023, the company has been observing encouraging signs within the business. During the first quarter of 2024, IB fees surged 21% on a year-over-year basis, with the company holding a market share of 9.1%. The company is expected to see growth in IB fees going forward, given a healthy IB pipeline and active merger &amp; acquisition (M&amp;A) market. It also intends to leverage its top position to amplify the magnitude of the gain due to the changed scenario.
JPMorgan has been expanding via both domestic and global acquisitions. Last year, the company increased its stake in Brazil&#39;s C6 Bank to 46% from 40%, established a strategic alliance with Cleareye.ai, a financial technology firm focused on trade finance and acquired Aumni and First Republic Bank (an FDIC-assisted deal). These deals, along with several others in the past, are likely to keep aiding the bank&#39;s plan to diversify revenues and expand fee income product suite and consumer bank digitally.
JPM currently carries a Zacks Rank #3 (Hold). In the past three months, shares of the company have gained 20% compared with the industry&#39;s growth of 15.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2d/70636.jpg?v=494358631" />
Image Source: Zacks Investment Research
Nonetheless, JPMorgan&#39;s excessive reliance on the performance of the capital markets to generate fee income is a matter of concern. Though increased volatility and a surge in client activity in 2022 led to improved trading performance, the same normalized on a gradual basis thereafter. The market&#39;s revenues dipped 4% on a year-over-year basis in 2023, with the trend continuing during the first quarter of 2024. The volatile nature of the business is likely to make growth challenging moving forward.
JPM&#39;s mortgage fees and related income performance turned dismal amid the continued rise in mortgage rates since 2022. This led to subdued demand for mortgage loans and refinancing. The metric witnessed a negative CAGR of 27.5% over the three years ended 2023. While the trend reversed during the first quarter of 2024, origination volumes and refinancing activities are unlikely to experience solid growth as mortgage rates are likely to stay elevated in the near term.
<h3>Banking Stocks Worth Considering</h3>
Some better-ranked banking stocks worth a look are Northrim BanCorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrim#NASDAQ">NRIM</a>) and Bank of Marin Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrc#NASDAQ">BMRC</a>), each sporting a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for NRIM&#39;s current-year earnings has been revised 12.2% upward in the past 60 days. The company&#39;s shares have risen 5.3% in the past six months.
The Zacks Consensus Estimate for BMRC&#39;s current-year earnings has been revised 5.7% upward in the past week. The company&#39;s shares have lost 22.7% in the past six months.
<a href="https://www.zacks.com/stock/news/2297790/jpmorgan-jpm-strategic-buyouts-aid-amid-fee-income-woes?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2297790">To read this article on Zacks.com click here.</a>

Federal Reserve

NRIM

JPMorgan Strategic Buyouts Aid Amid Fee Income Woes

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Outperform and maintains $21 price target.

Keefe, Bruyette & Woods Maintains Outperform on Bank of Marin, Maintains $21 Price Target

In the preceding three months, 4 analysts have released ratings for Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.0, a high estimate of $21.00, and a low estimate of $15.00. Highlighting a 11.69% decrease, the current average has fallen from the previous average price target of $19.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1719500479_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Bank of Marin is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jeff Rulis</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank of Marin. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bank of Marin compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bank of Marin's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Bank of Marin's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bank of Marin analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Bank of Marin</h2>
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
<h3>Understanding the Numbers: Bank of Marin's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Bank of Marin faced challenges, resulting in a decline of approximately -24.85% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Bank of Marin's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bank of Marin's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Bank of Marin's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.08%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Bank of Marin's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Bank of Marin

Stephens &amp; Co. analyst Andrew Terrell reiterates Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Equal-Weight and maintains $16 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Bank of Marin, Maintains $16 Price Target

The securities sold represented&nbsp;56%&nbsp;of the AFS portfolio and had an average yield of&nbsp;1.94%. The sale will result in an estimated after-tax loss of approximately&nbsp;$23 million&nbsp;that will be recorded in the&nbsp;second quarter&nbsp;of 2024.&nbsp;
Assuming a&nbsp;5.75%&nbsp;average yield on reinvestment, the securities repositioning is expected to have an approximate 3-year capital earn back and contribute approximately 30 basis points to annualized net interest margin beginning&nbsp;third quarter, resulting in&nbsp;$0.46&nbsp;estimated earnings per share accretion over the next four quarters.
&nbsp;

Asset Sales

Bank Of Marin Reports Sale Of $293M In Available-For-Sale Securities To Improve Future Earnings And Increase Its Return On Equity

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Outperform and lowers the price target from $25 to $21.

Keefe, Bruyette & Woods Maintains Outperform on Bank of Marin, Lowers Price Target to $21

DA Davidson analyst Jeff Rulis maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Neutral and lowers the price target from $17 to $15.

DA Davidson Maintains Neutral on Bank of Marin, Lowers Price Target to $15

Stephens &amp; Co. analyst Andrew Terrell maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Equal-Weight and lowers the price target from $19 to $16.

Stephens & Co. Maintains Equal-Weight on Bank of Marin, Lowers Price Target to $16

Bank of Marin Bancorp: Undervalued With Over 5% Dividend Yield, But Risks Are High

Revisiting Bank of Marin Results In A Downgrade

Bank Of Marin Bancorp ( ($BMRC) ) has issued an announcement. Bank of Marin Bancorp will hold a webcast on October 28, 2024, to discuss its third-q...

Bank of Marin Bancorp Q3 Financial Results Webcast Announcement

Bank Of Marin Bancorp (BMRC – Research Report) received a Buy rating and a price target from D.A. Davidson analyst Jeff Rulis today. The company's ...

Positive Report for Bank Of Marin Bancorp (BMRC) from D.A. Davidson

Bank of Marin Bancorp Non-GAAP EPS of $0.28 beats by $0.03, revenue of $27.16M misses by $0.46M

Bank of Marin Bancorp declares $0.25 dividend

In a report released today, Wood Lay from KBW maintained a Buy rating on Bank Of Marin Bancorp (BMRC – Research Report), with a price target of $23...

Bank Of Marin Bancorp (BMRC) Gets a Buy from KBW

D.A. Davidson analyst Jeff Rulis reiterated a Buy rating on Bank Of Marin Bancorp (BMRC – Research Report) today. The company's shares closed yeste...

D.A. Davidson Sticks to Their Buy Rating for Bank Of Marin Bancorp (BMRC)

Bank Of Marin Bancorp ( ($BMRC) ) has shared an announcement. Bank of Marin Bancorp is set to participate in the Keefe Bryuette & Woods Virtual Wes...

Bank of Marin Bancorp Highlights Growth and Stability

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Bank Of Marin Bancorp (BMRC – Research Report), XP ...

Analysts' Opinions Are Mixed on These Financial Stocks: Bank Of Marin Bancorp (BMRC), XP (XP) and Golub Capital Bdc (GBDC)

FSBW

GBDC

VBNK

WTBA

Press Releases

Bank of Marin Bancorp to Webcast Q4 Earnings on Monday, January 29, 2024, at 8:30 a.m. PT

Bank of Marin Bancorp Reports Fourth Quarter and Full Year 2023 Earnings

Bank of Marin Bancorp Announces Retirement of Robert Heller from Board of Directors

Comments

Bank of Marin

Bank of Marin (BMRC) Opzioni

Bank of Marin (NASDAQ:BMRC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO